WCN25-2760 Complement receptor C5aR1 correlates with inflammatory responses driven by glomerular uPAR upregulation in renal vasculitides

kidney disease therapy due to their antiapoptotic, immunomodulatory, antioxidative, and pro-angiogenic activities (4-6).However, the clinical translation of the same is at a miniscule level (7,8).In this study, we have preconditioned MSCs with formulation A for them to exert a strong anti-fibrotic effect in conjunction with anti-inflammatory and immunomodulatory effects.Since the preconditioning is exerting these effects in in vitro models of primary cultures of kidney-derived cells, we plan to test this hypothesis in the AKI-CKD animal model.Methods: Primary cell culture of interstitial fibroblasts was established by sieving method (9).The MSCs were isolated from the explant culture of Wharton jelly from the discarded clinical waste after patients' due consent.Both cell types were cultured, and characterized in GMP-compliant facilities.MSCs were preconditioned with formulation A at a standardized concentration and time point, the concentrated conditioned medium was collected by using centrifugal filters (cut-off 3kDa MW).The concentrated medium from these cells was tested in a cisplatin-mediated injury model of interstitial fibroblasts.The efficacy of MSCs was checked in terms of their viability, phenotyping, and functional capabilities like immunomodulation.Endpoints of in vitro work were studied in the context of inflammatory markers by ELISA and fibrotic markers by immunofluorescence.Results: We have shown that the specific preconditioning of MSCs improves their immunomodulation capability markedly while maintaining a good viability score.Moreover, the secretome from these MSCs imparts an anti-inflammatory and anti-fibrotic milieu in the in vitro injury and diseased models of human kidney-derived primary interstitial fibroblast cells.Conclusions: We have demonstrated that conditioned MSC secretome treatment to a diseased milieu of primary human kidney cells leads to a decrease in the expression of apoptotic, fibrotic, and inflammatory markers.Here, we propose that this secretome-based intervention could be an ideal therapeutic contender once tested in a preclinical model because:-It is a cell-free therapy, and It has the potential to generate an offshelf therapeutic product.